← Back to Search

Other

RCT Determining Best Treatment for Geriatric Acetabular Fractures (GeriTab Trial)

N/A
Waitlist Available
Led By Theodore Manson, MD
Research Sponsored by University of Maryland, College Park
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

There is debate over the best management for acetabular (hip) fractures that occur within the geriatric population. Geriatric patients, 60 years or older, are at greater risk for operative complications because they tend to have poorer bone quality, complicated fractures, and multiple health problems. Physicians currently have no guidelines as to the best surgical management for these particular fractures, because there is little data on the long-term outcomes of these injuries. The use of internal fixation (a nail or plate) is a standard method for repairing these injuries, however when the injuries are complicated it is predicted to have a poorer outcome than performing internal fixation along with total hip arthroplasty (joint reconstruction). Given the significant problems that result from hip fractures in this population, our study is designed to determine the best method for treatment of acetabular fractures and to clarify the criteria for treatment with guidelines assisting the physician in selecting the appropriate treatment.

Eligible Conditions
  • Acetabular Fracture

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The measure for this study is the proportion of complications in the first 12 months following surgery
Secondary study objectives
A for this study is to evaluate patient reported outcomes using the SF36 Questionnaire.
A for this study is to evaluate patient reported outcomes using the WOMAC Questionnaire.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Active Control
Group I: RCT - ORIFActive Control1 Intervention
A patient in this study arm consents to randomization and receives RCT - ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation.
Group II: OBS - ORIFActive Control1 Intervention
A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation.
Group III: RCT - (THA) + ORIFActive Control1 Intervention
A patient in this study arm consents to randomization and receives RCT - (THA) + ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
Group IV: OBS (THA) + ORIFActive Control1 Intervention
A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.

Find a Location

Who is running the clinical trial?

University of Maryland, College ParkLead Sponsor
159 Previous Clinical Trials
46,410 Total Patients Enrolled
University of MarylandLead Sponsor
169 Previous Clinical Trials
306,888 Total Patients Enrolled
University of Maryland, BaltimoreLead Sponsor
716 Previous Clinical Trials
381,056 Total Patients Enrolled
Theodore Manson, MDPrincipal InvestigatorAssociate Professor of Orthopaedics
~4 spots leftby Jan 2026